



HHS Public Access

Author manuscript

Psychol Med. Author manuscript; available in PMC 2018 February 14.

Published in final edited form as:

Psychol Med. 2016 June ; 46(8): 1613–1623. doi:10.1017/S0033291715002081.

Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies

A full list of authors and affiliations appears at the end of the article.

Abstract

Background—Major depressive disorder (MDD) is moderately heritable, however genome-wide association studies (GWAS) for MDD, as well as for related continuous outcomes, have not shown consistent results. Attempts to elucidate the genetic basis of MDD may be hindered by heterogeneity in diagnosis. The Center for Epidemiological Studies Depression (CES-D) scale provides a widely used tool for measuring depressive symptoms clustered in four different domains which can be combined together into a total score but also can be analysed as separate symptom domains.

Method—We performed a meta-analysis of GWAS of the CES-D symptom clusters. We recruited 12 cohorts with the 20-or 10-item CES-D scale (32 528 persons).

Results—One single nucleotide polymorphism (SNP), rs713224, located near the brain-expressed melatonin receptor (*MTNR1A*) gene, was associated with the somatic complaints domain of depression symptoms, with borderline genome-wide significance ($p_{\text{discovery}} = 3.82 \times 10^{-8}$). The SNP was analysed in an additional five cohorts comprising the replication sample (6813 persons). However, the association was not consistent among the replication sample ($p_{\text{discovery} + \text{replication}} = 1.10 \times 10^{-6}$) with evidence of heterogeneity.

Conclusions—Despite the effort to harmonize the phenotypes across cohorts and participants, our study is still underpowered to detect consistent association for depression, even by means of symptom classification. On the contrary, the SNP-based heritability and co-heritability estimation results suggest that a very minor part of the variation could be captured by GWAS, explaining the reason of sparse findings.

Keywords

Genome-wide association studies; major depressive disorder; meta-analyses

*Address for correspondence: J. Lahti, Institute of Behavioural Sciences, University of Helsinki, Siltavuorenpenger 1A, 00014 Helsingin yliopisto, Finland. (jari.lahti@helsinki.fi).

†These authors contributed equally.

Supplementary material

To view supplementary material for this article, please visit <http://dx.doi.org/10.1017/S0033291715002081>

Declaration of Interest

None.

Introduction

Genetic factors play an important role in the susceptibility to depression. A meta-analysis of twin studies on major depressive disorder (MDD) estimated the heritability between 31 and 42% (Sullivan *et al.* 2000). The success of genome-wide association studies (GWAS) aiming to find genes underlying vulnerability for depression, however, has been limited; the most promising findings to date are poorly replicated and explain only a small proportion of this heritability (Muglia *et al.* 2008; Psychiatric GWAS Case Control Consortium *et al.* 2009; Sullivan *et al.* 2009). This may be explained by the polygenic architecture of the trait as well as difficulties in diagnosis. A validated biomarker for depression does not exist and the diagnosis is based solely on symptoms. Such symptoms include depressed mood states, loss of interest in activities, feelings of worthlessness or inappropriate guilt, recurrent thoughts of death, poor concentration, and somatic symptoms such as changes in appetite, sleep patterns, fatigue, and weight gain or loss (American Psychiatric Association, 1994; National Institute for Clinical Excellence, 2003). Depression can manifest with different patterns of symptoms, and such phenotypic heterogeneity may reflect genetic heterogeneity. It is plausible that different genetic pathways are associated with the various symptom clusters, and analyses of more narrowly defined phenotypes may reduce genetic heterogeneity. Indeed, the diverse domains of complaints, which result in variations in presentation of the disease within and between populations, may lead to problems for gene discovery. A focus on outcomes based on depressive symptoms and endophenotypes has been shown to increase power in association studies (Teslovich *et al.* 2010; van der Sluis *et al.* 2013). However, the genetic architecture of these outcomes is also complex and may involve the effects of multiple common variants (Demirkan *et al.* 2011).

Depressive symptoms can be measured by questionnaires, such as the Center for Epidemiological Studies Depression (CES-D) scale, which shows moderate heritability (López-León *et al.* 2010). The CES-D scale measures symptoms clustered in somatic complaints, lack of positive affect, negative affect and interpersonal problems domains, which are usually combined into a single score (Radloff, 1977). The CES-D subscales can also be analysed separately in order to focus on the specific symptom domains. We conducted a meta-analysis of GWAS of specific symptom domains measured by the CES-D scale. The discovery set consisted of 12 cohorts ($n = 32\,528$) and the replication set consisted of five cohorts ($n = 6813$).

Method

Table 1 summarizes the characteristics of the discovery and replication cohorts from the Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE) Consortium. The main aim of CHARGE is to facilitate GWAS meta-analyses and replication opportunities among multiple large and well-phenotyped longitudinal cohort studies (Psaty *et al.* 2009). The discovery sample consisted of the CHARGE cohorts with eligible 20-item CES-D (CES-D-20) data. These cohorts were the Baltimore Longitudinal Study of Aging (BLSA) (Sutin & Zonderman, 2012), the Dortmund Health Study (Vennemann *et al.* 2008; Pfaffenrath *et al.* 2009), the Erasmus Rucphen Family Study (ERF) (Aulchenko *et al.* 2004; López-León *et al.* 2009), the *National Heart, Lung, and Blood Institute's* Framingham Heart

Study (FHS) (Dawber *et al.* 1951; Feinleib *et al.* 1975; Splansky *et al.* 2007), the Helsinki Birth Cohort Study (HBCS) (Barker *et al.* 2005), European ancestry participants from the Health, Aging and Body Composition study (HEALTH ABC-Eur) (Cesari *et al.* 2003), the Rotterdam Study I-II and III (RS I-II and RS-III) (Hofman *et al.* 2011) and SardiNIA (Pilia *et al.* 2006) and two studies in which the symptoms of depression were measured with the 10-item version of CES-D (CES-D-10): the Atherosclerosis Risk In Communities (ARIC) study (ARIC Investigators, 1989) and the Swedish Twin Registry (STR) study (Rahman *et al.* 2009). FINRISK (Vartiainen *et al.* 2010), the Health and Retirement Study (HRS) (Juster & Suzman, 1995; Weir, 2008), Invecchiare in Chianti (InCHIANTI), and the Memory and Aging Project and Religious Order Study of Rush Alzheimer's Disease Center (RUSH-ROS and RUSH-MAP) (Bennett *et al.* 2005; Bennett, 2006) were used as replication analysis of rs713224 (see online Supplementary text S1 for the study descriptions and online Supplementary text S2 for the items of the CES-D scale). With these sample sizes, we had about 80% power to detect associations that explain about 0.12% of the trait variation in the discovery cohort and replication cohort with a p value of 5×10^{-8} and 0.05, respectively. In the case of multiple measurements the study centers preferred to analyse the measurements that maximize the number in the analysis. This is usually the first measurement as the response declines by years of follow-up. In this case the mean age of the samples refers to the time of measurement date.

GWAS analyses were performed individually by the study centers, according to the same analysis plan; each study excluded dementia cases (Mini-Mental State Examination score < 22), and anti-depressive medication users (except BLSA), since the effect of anti-depressive medication on the scales was not consistent across the studies. There was no restriction on age. Each study center computed the subscales of the CES-D questionnaire that resulted in four separate scores for each individual, measuring different domains of complaints. The reliability coefficients (Cronbach's α) for the somatic complaints (seven items), lack of positive affect (four items) and negative affect (seven items) domains were adequate and ranged from 0.68 to 0.84 whereas for the interpersonal problems domain (two items) those were between 0.45 and 0.63 for the 20-item CES-D scale cohorts. For the 10-item scale, Cronbach's α 's for the somatic complaints (three items) ranged from 0.52 to 0.78 and for lack of positive affect (two items) and negative affect (three items) between 0.64 and 0.71. Each study implemented linear regression models, adjusted for age, age-square and sex, under the assumption of an additive genetic model, regressing each subscale on allele dosage and reported the summary statistics. The genotyping and imputation methods for each study are given in online Supplementary Table S1. Additional study site-specific adjustments included linear mixed-effect models to account for familial correlations in the FHS and ERF, and adjustment for the top three Eigen vectors in RUSH-MAP, RUSH-ROS and STR. Prior to meta-analysis, all single nucleotide polymorphism (SNP) IDs were mapped to dbSNP Build 129. Possible measurement and scoring differences across different study centers were checked through extracting the median standard error from the GWAS summary statistics of each study center and plotting it against the square-root of the sample size. Allele frequencies for all SNPs were compared with HapMap frequencies. Stratified Q-Q plots were generated for minor allele frequency (MAF) and imputation quality strata to assess potential sources of inflation. Meta-analyses were performed using the sample size-weighted

method as implemented in METAL software package (Willer *et al.* 2010). Due to poor psychometric properties and differences in the median standard errors across the cohorts we excluded the interpersonal problems domain from further analysis. Furthermore, this domain has been criticized for not being consistent with the current criteria for depression and therefore introducing confounding in the validity of the CESD (Carleton *et al.* 2013). SNPs with a MAF less than 2.5% or an observed:expected variance ratio (imputation quality) less than 0.30 were excluded on a per-study basis. SNPs for which the total sample size was lower than 5000 were removed from further analysis. We did not use genomic control as this method has been shown to be too conservative (Bulik-Sullivan *et al.* 2015). SNP-based heritability was calculated using 1 069 063 markers that were common in the meta-analyses results and linkage disequilibrium (LD) scores were computed using the 1000 Genomes Central Europe (CEU) reference panel as suggested by the tutorials and provided by the developers of the method.

To test the amount of variance explained by the genetic risk score, we performed a genetic risk score analysis. We excluded one of the cohorts (RS I) ($n = 3709$) from the discovery set and used this cohort as the target sample. The total score for individuals was calculated for each set of SNPs that were defined on the basis of the p values in the discovery set (e.g. $p < 0.00001, 0.0001, 0.1, 0.2$). Genetic risk scores were calculated by multiplying the Z -score that was obtained in the discovery analyses with the risk alleles per SNP (0, 1, 2). The PLINK toolset was used to calculate the risk scores (Purcell *et al.* 2007). Linear regression analysis was used to test the association of the genetic risk scores with somatic item scores in the target sample.

Results

The inflation factors for the discovery GWAS of the three scales varied between 1.026 and 0.984. We did not observe any genome-wide significant SNPs for any of the scales in the discovery set apart from the top SNP, rs713224, that showed significant association with the somatic complaints scale ($p_{\text{discovery}} = 3.82 \times 10^{-8}$). Q-Q plots and Manhattan plots of this analysis are presented in the online Supplementary Figs S1 and S2. Online Supplementary Table S2 shows the SNPs with $p < 10^{-4}$ from the discovery set of 32 528 persons for the somatic, positive and negative domains. The analysis of rs713224 was further extended to a second stage, which included 6813 persons from five study samples, as shown in Table 1. Study-specific summary results for rs713224 are given in online Supplementary Table S3. The overall analysis yielded a non-significant result ($p_{\text{discovery+replication}} = 1.10 \times 10^{-6}$) in the genome-wide scale. Testing for heterogeneity showed evidence for outliers ($p_{\text{het}} = 0.07$) in the combined analysis, compared with the discovery phase ($p_{\text{het}} = 0.17$).

SNP-based heritability estimates (h^2) were 0.038 (S.E. = 0.01), 0.01 (S.E. = 0.01) and 0.024 (S.E. = 0.01) for the somatic, positive and negative domains, respectively. The somatic and negative domains showed significant co-heritability (genetic correlation: 1.1, S.E. = 0.23, Z -score = 4.6, $p = 4.3 \times 10^{-6}$). The positive domain did not show significant genetic correlation with the negative domain (genetic correlation: 1.5, S.E. = 1.4, Z -score = 1.1, $p = 0.27$) or with the somatic domain (genetic correlation: 1.5, S.E. = 1.3, Z -score = 1.1; $p = 0.27$).

In order to search for possible real associations among the subthreshold loci we have performed also a risk score analysis using the discovery set after excluding one of the cohorts as discovery and the RS as the training set. The SNPs with p values less than 10^{-5} explained a significant but very small part of the variance on the somatic items scale ($p = 0.001$, $R^2 = 0.3\%$) (online Supplementary Fig. S4).

Discussion

We conducted a GWAS on specific symptom domains of depression in which we combined the results of 12 population-based studies including 32 528 individuals to find common variants that increase the vulnerability to a particular symptom domain (somatic complaints, lack of positive affect and negative affect). In the discovery set we found evidence for one SNP near the brain-expressed melatonin receptor (*MTNR1A*) gene with respect to the somatic complaints domain only ($p_{\text{discovery}} = 3.82 \times 10^{-8}$). This is in line with an earlier study showing that symptoms of depression linked with physiological functions may show higher heritability compared with symptoms related to negative affect (Jang *et al.* 2004). Rs713224 was further analysed in five separate samples and also in combined meta-analyses of the discovery and replication sets. However, the level of significance of this SNP was attenuated ($p_{\text{discovery+replication}} = 1.10 \times 10^{-6}$). The negative and positive domains did not yield any genome-wide significant SNPs.

Our top SNP, rs713224, is located near the *MTNR1A* gene, which encodes one of the two melatonin receptors expressed in the brain. Melatonin is a circadian and seasonal regulator in many organisms including humans and is secreted in darkness by the pineal gland. Although melatonin is the hormone of the pineal gland, *MTNR1A* is ubiquitously expressed, predominantly in the suprachiasmatic nucleus, hypothalamus and prefrontal cortex. The melatonin receptor pathway is known to be involved in depression (Carman *et al.* 1976; Wetterberg *et al.* 1984; Goldstein, 1985; Bourin & Prica, 2009; Anderson, 2010; Gałecka *et al.* 2011) and its relationship with somatic complaints, and vitality in general, makes it a biologically plausible gene.

However, lack of replication raises the conclusion that our finding for this SNP is likely to be a false positive. Among other reasons, population stratification can result in false-positive findings. To avoid population stratification, only individuals of European descent were included in this study. Including only individuals from population-based studies of European descent also minimized measurement error caused by cultural differences in response to the CES-D (Bernert *et al.* 2009). On the other hand, this does not count for the replication set. Among them, for instance the RUSH sample included more women and older persons and reported very low mean values for the somatic items (Table 1). Difference in age across the study samples can introduce heterogeneity since melatonin and melatonin receptors are shown to decrease by age (Hill *et al.* 2013). An additional sensitivity analysis, excluding the RUSH study, yielded a $p_{\text{discovery+replication}} = 4.96 \times 10^{-7}$ and decreased the heterogeneity ($p_{\text{het}} = 0.08$), but did not exclude it completely. A particular reason of heterogeneity for the melatonin receptor signaling-related outcomes is the interaction with melatonin levels as reviewed extensively before (Pandi-Perumal *et al.* 2008) and therefore the influence on depressive symptoms may be season specific, depending on the calendar time and latitude

that the depression screening took place. However, it was not possible to control for this in the current study.

Although our study is among the largest ones conducted thus far on the common genomic variation in depression with power to detect effects explaining 0.12% of the variation, our study failed to clearly detect and replicate a single loci related to symptoms of depression. Among several reasons, one is that the trait may not be genetically controlled.

The CES-D questionnaire measures depressive symptoms in the past week and the total CES-D scale has been shown to be conserved through life (Radloff, 1977), while this does not rule out the fact that responses to different symptom clusters may differ throughout the lifetime as there is no study to our knowledge that has focused on this. In addition, responses to specific symptom clusters may be population specific due to cultural acceptance or practices. Moreover, age differences across the CHARGE cohorts might have played a role as presentation of depressive symptoms strongly differs by age whereas some genetic variants are hypothesized to interact with age (Simino *et al.* 2014). These would probably introduce phenotypic and genetic heterogeneity. To see if the individual studies were indeed genetically controlled we estimated the SNP-based heritability from the separate GWAS summary statistics collected in this research. The SNP-based heritability estimations in the meta-analysis were surprisingly low (1–4%), indicating the reason for the sparse findings. This is partially due to several reasons sourcing from the genetic architecture of the traits, which are not adequately addressed by the simple association models; such as exclusion of X chromosome, and limiting the analysis only with an additive genetic model which deviates from sufficient power when the MAF < 0.5. Another important reason is that interaction of any genetic determinant with stressful life events, traumas, therapeutic agents, smoking or menopause, which may confer risk to depression (Keers & Uher, 2012), were neglected. We further estimated the co-heritability to see if there are genetic outliers amongst the meta-analysis cohorts. This revealed surprisingly low co-heritability across the contributing cohorts, explaining the lack of successful meta-analysis and replication in our study. The low co-heritability estimations are the indicators of high genetic and phenotypic heterogeneity across the cohorts and are the plausible explanation of insignificant replication in our research. Here it is important to note that the estimates from LD score regression have to be treated with caution because of the small sample size in some individual cohorts.

We also considered the possibility that individual common SNPs explain only a very small proportion of some complex traits, as shown by the polygenic risk score analyses in the current study in which only 0.3% of variance was explained by the most significant SNPs. The risk score for the remaining thresholds did not improve the explained variance, contrary to previous reports (Demirkan *et al.* 2011). Previous studies exploring complex traits (e.g. educational attainment, MDD) revealed similar results (Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium *et al.* 2013; Rietveld *et al.* 2013).

The difficulty in finding and replicating GWAS signals for major depression has been a common experience both for depressive symptoms and MDD. A previous study of depressive symptoms of the CHARGE Consortium (Hek *et al.* 2013) on a partially overlapping sample suggested a region on 5q21 in a combined analysis of more than 50 000

persons. A meta-analysis of eight GWAS of MDD status (about 6000 MDD cases and about 7000 controls) yielded only one genome-wide significant finding in the solute carrier family 6 member 15 gene (*SLC6A15*) (Kohli *et al.* 2011), while the recent Psychiatric Genomics Consortium (PGC) mega-analysis (9238 cases and 8039 controls) pointed out one region on 3p21.1 that reached genome-wide significance; however, to our knowledge no replication has been reported so far. A PGC-MDD GWAS also showed an association of rs4478239, located within 800 kB of *MTNRI1A*, with recurrent depression ($p = 4.7 \times 10^{-7}$) in a study including 6743 cases and 9519 controls (online Supplementary Fig. S3). However, the proxy for our top SNP in that region (rs2375800) was not associated with MDD. Similarly, we were not able to replicate the two main findings of a recent report by the CONVERGE Consortium (2015) who attributed their success to the recruitment of relatively homogeneous cases with severe illness. For the *LHPP* gene region the proxy SNP rs12258489 yielded insignificant p values for negative items (Z -score = 1.52, $p = 0.12$), for positive items (Z -score = -0.52, $p = 0.59$) and for somatic items (Z -score = 1.23, $p = 0.22$). For the sirtuin 1 (*SIRT1*) region, the SNP of interest, rs12415800, did not associate with negative items (Z -score = 0.12, $p = 0.89$), positive items (Z -score = -0.57, $p = 0.56$) or somatic items scales (Z -score = 1.81, $p = 0.07$).

Conclusion

To conclude, our efforts in a large collaboration utilizing phenotypes defined by symptom clustering yielded no genome-wide significant hit except the somatic complaints domain. One SNP, associated with somatic complaints, reached genome-wide significance in the combined sample and suggested the involvement of *MTNRI1A* in the melatonin signaling pathway, but was not further replicated. Our results suggest that GWAS for depression in large population-based samples remain underpowered due to phenotypic and genetic heterogeneity.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

A. Demirkan^{1,†}, J. Lahti^{2,*†}, N. Direk^{3,†}, A. Viktorin⁴, K. L. Lunetta⁵, A. Terracciano^{6,7}, M. A. Nalls⁸, T. Tanaka⁶, K. Hek^{3,9}, M. Fornage¹⁰, J. Wellmann¹¹, M. C. Cornelis¹², H. M. Ollila¹³, L. Yu¹⁴, J. A. Smith¹⁵, L. C. Pilling¹⁶, A. Isaacs¹, A. Palotie^{17,18}, W. V. Zhuang¹⁹, A. Zonderman⁶, J. D. Faul²⁰, A. Sutin⁶, O. Meirelles⁶, A. Mulas²¹, A. Hofman³, A. Uitterlinden^{3,22,23}, F. Rivadeneira^{3,22,23}, M. Perola¹³, W. Zhao²⁰, V. Salomaa²⁴, K. Yaffe²⁵, A. I. Luik³, NABEC²⁶, UKBEC²⁷, Y. Liu²⁸, J. Ding²⁹, P. Lichtenstein⁴, M. Landén⁴, E. Widen¹⁸, D. R. Weir²⁰, D. J. Llewellyn¹⁶, A. Murray¹⁶, S. L. R. Kardia²⁰, J. G. Eriksson^{30,31}, K. Koenen³², P. K. E. Magnusson⁴, L. Ferrucci⁶, T. H. Mosley³³, F. Cucca²¹, B. A. Oostra^{1,34}, D. A. Bennett¹⁴, T. Paunio¹³, K. Berger¹¹, T. B. Harris³⁵, N. L. Pedersen⁴, J. M. Murabito³⁶, H. Tiemeier³, C. M. van Duijn^{1,22}, and K. Räikkönen²

Affiliations

¹Genetic Epidemiology Unit, Departments of Epidemiology and Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands ²Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland ³Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands ⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden ⁵Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA ⁶National Institute on Aging, National Institutes of Health, Baltimore, MD, USA ⁷College of Medicine, Florida State University, Tallahassee, FL, USA ⁸Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA ⁹Department of Psychiatry, Epidemiological and Social Psychiatric Research Institute, Erasmus MC, Rotterdam, The Netherlands ¹⁰Houston Institute of Molecular Medicine, University of Texas, Houston, TX, USA ¹¹Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany ¹²Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA ¹³Public Health Genomics Unit and Institute for Molecular Medicine Finland (FIMM), National Institute for Health and Welfare, Helsinki, Finland ¹⁴Department of Neurological Sciences, Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA ¹⁵Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA ¹⁶University of Exeter Medical School, Exeter, UK ¹⁷Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK ¹⁸Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland ¹⁹Department of Preventive Medicine and Public Health, School of Medicine, Creighton University, Omaha, NE, USA ²⁰Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA ²¹Istituto di Ricerca Genetica e Biomedica, CNR, Monserrato, Cagliari, Italy ²²Member of Netherlands Consortium for Healthy Aging sponsored by Netherlands Genomics Initiative, Leiden, The Netherlands ²³Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands ²⁴Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland ²⁵Departments of Psychiatry, University of California, San Francisco, CA, USA ²⁶North American Brain Expression Consortium, USA ²⁷UK Brain Expression Consortium, UK ²⁸Center for Human Genomics, Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA ²⁹Geriatrics & Gerontology, Sticht Center on Aging, Wake Forest University, Primate Center, Epidemiology & Prevention, Winston-Salem, NC, USA ³⁰National Institute for Health and Welfare, Helsinki, Finland ³¹Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland ³²Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA ³³Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA ³⁴Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands ³⁵Laboratory of Epidemiology, Demography, and Biometry, National Institute on Ageing, National Institutes of Health, Bethesda, MD,

USA ³⁶Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA, USA

Acknowledgments

ARIC study

The research is carried out as a collaborative study supported by: National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, and grants R01-HL087641, R01-HL093029 and R01-HL70825; National Human Genome Research Institute contract U01-HG004402; and National Institutes of Health (NIH) contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by grant number UL1RR025005, a component of the NIH Roadmap for Medical Research.

BLSA

BLSA research was supported by the Intramural Research Program of the NIH, National Institute on Aging.

Dortmund Health Study

Blood collection in the Dortmund Health Study was funded by the Institute of Epidemiology and Social Medicine, University of Münster and genotyping with the HumanOmni chip by the German Ministry of Research and Education (BMBF, 01ER0816). The collection of sociodemographic and clinical data in the Dortmund Health Study was supported by the German Migraine & Headache Society (DMKG) and by unrestricted grants of equal share from Almirall, Astra Zeneca, Berlin Chemie, Boehringer, Boots Health Care, Glaxo-Smith-Kline, Janssen Cilag, McNeil Pharma, MSD Sharp & Dohme and Pfizer to the University of Münster.

ERF study

The genotyping for the ERF study was supported by EUROSPAN (European Special Populations Research Network) and the European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by grants from the Netherlands Organization for Scientific Research, Erasmus MC, the Centre for Medical Systems Biology (CMSB) and the Netherlands Brain Foundation (HersenStichting Nederland). We are grateful to all participating individuals and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

FHS

The phenotype–genotype association analyses in the FHS were supported by R01-AG29451. This research was conducted in part using data and resources from the FHS of the National Heart, Lung, and Blood Institute of the NIH and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the FHS investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung, and Blood Institute's FHS (contract no. N01-HC-25195) and its contract with Affymetrix, Inc. for genotyping services (contract no. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center.

FINRISK

The FINRISK Study has been funded by the Sigrid Juselius Foundation, the Jalmari and Rauha Ahokas Foundation and the Biomedicum Helsinki Foundation.

HEALTH ABC-Eur

This research was supported by National Institute on Aging contracts N01AG62101, N01AG62103 and N01AG62106. The GWAS was funded by National Institute on Aging grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). The CIDR is fully funded through a federal contract from the NIH to The Johns Hopkins University (contract number HHSN268200782096C).

HBCS

We thank all study participants as well as everybody involved in the HBCS. The HBCS has been supported by grants from the Academy of Finland, the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, University of Helsinki, European Science Foundation (EUROSTRESS), Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation and the Wellcome Trust (grant number WT089062).

HRS

The HRS is supported by the National Institute on Aging (NIA U01AG009740). The genotyping was funded as a separate award from the National Institute on Aging (RC2 AG036495). Our genotyping was conducted by the NIH CIDR at Johns Hopkins University. Genotyping quality control and final preparation of the data were performed by the Genetics Coordinating Center at the University of Washington.

InCHIANTI

The InCHIANTI Study was supported as a 'targeted project' (ICS 110.1RS97.71) by the Italian Ministry of Health, by the US National Institute on Aging (contracts N01-AG-916413, N01-AG-821336, 263 MD 916413 and 263 MD 821336) and in part by the Intramural Research Program, National Institute on Aging, NIH, USA.

RS

The generation and management of the genotype data for the RS are supported by the Netherlands Organization of Scientific Research Investments (no. 175.010.2005.011, 911-03-012). The RS is funded by: the Erasmus Medical Center and Erasmus University, Rotterdam; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE and RIDE2); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); the Municipality of Rotterdam; and the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research project number 050-060-810.

RUSH-ROS

The RUSH-ROS study was supported by National Institute on Aging grant P30AG10161 and the Illinois Department of Public Health.

RUSH-MAP

The RUSH-MAP study was supported by National Institute on Aging grants R01AG17917 and R01AG15819, and by the Illinois Department of Public Health.

SardiNIA

SardiNIA research was supported by the Intramural Research Program of the NIH, National Institute on Aging. M.C.C. is a recipient of a NARSAD Young Investigator Award. Funding was also provided through contract NO1-AG-1-2109 from the National Institute on Aging, NIH.

TWINGENE

The STR study was supported by The Ministry for Higher Education, the Swedish Research Council (M-2005-1112), GenomEUtwin (EU/QLRT-2001-01254; QLG2-CT-2002-01254), NIH DK U01-066134, the Swedish Foundation for Strategic Research (SSF) and the Heart and Lung Foundation (no. 20070481).

North American Brain Expression Consortium (NABEC) brain expression quantitative trait loci (eQTL) data

The work performed by the NABEC was supported in part by the Intramural Research Program of the National Institute on Aging, NIH, part of the US Department of Health and Human Services; project number ZIA AG000932-04. In addition this work was supported by a Research Grant from the Department of Defense, W81XWH-09-2-0128. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the NIH, Bethesda, MD (<http://biowulf.nih.gov>). NABEC scientists are Andrew B. Singleton, Mark R. Cookson, J. Raphael Gibbs, Dena G. Hernandez, Alissa Dilman, Michael A. Nalls, Alan B. Zonderman, Sampath Arepalli, Luigi Ferrucci, Robert Johnson, Dan L. Longo, Richard O'Brien, Bryan Traynor, Juan Troncoso and Marcel van der Brug.

UK Brain Expression Consortium (UKBEC) Brain eQTL data

UKBEC scientists are John Hardy, Michael E. Weale, Mina Ryten, Adaikalavan Ramasamy, Daniah Trabzuni, Colin Smith, H. Ronald Zielke and Robert Walker. These studies performed by the UKBEC were supported by the Medical Research Council (MRC) through the MRC Sudden Death Brain Bank (C.S.), by a project grant (G0901254 to J.H. and M.W.) and by a fellowship award (G0802462 to M.R.). D.T. was supported by the King Faisal Specialist Hospital and Research Centre, Saudi Arabia. Computing facilities used at King's College London were supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. We would like to thank AROS Applied Biotechnology AS company laboratories and Affymetrix for their valuable input (PMID: 20485568, PMID: 21848658 and PMID: 227230.18).

References

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th. American Psychiatric Association; Washington, DC: 1994.
- Anderson G. The role of melatonin in post-partum psychosis and depression associated with bipolar disorder. *Journal of Perinatal Medicine*. 2010; 38:585–587. [PubMed: 20707614]
- ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC Investigators. *American Journal of Epidemiology*. 1989; 129:687–702. [PubMed: 2646917]
- Aulchenko YS, Heutink P, Mackay I, Bertoli-Avella AM, Pullen J, Vaessen N, Rademaker TAM, Sandkuijl LA, Cardon L, Oostra B, van Duijn CM. Linkage disequilibrium in young genetically isolated Dutch population. *European Journal of Human Genetics*. 2004; 12:527–534. [PubMed: 15054401]
- Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. *New England Journal of Medicine*. 2005; 353:1802–1809. [PubMed: 16251536]
- Bennett DA. Postmortem indices linking risk factors to cognition: results from the Religious Order Study and the Memory and Aging Project. *Alzheimer Disease and Associated Disorders*. 2006; 20(Suppl. 2):S63–S68. [PubMed: 16917198]
- Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. *Neuroepidemiology*. 2005; 25:163–175. [PubMed: 16103727]
- Bernert S, Matschinger H, Alonso J, Haro JM, Brugha TS, Angermeyer MC, E.S.M. Investigators. Is it always the same? Variability of depressive symptoms across six European countries. *Psychiatry Research*. 2009; 168:137–144. [PubMed: 19481817]
- Bourin M, Prica C. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. *Current Pharmaceutical Design*. 2009; 15:1675–1682. [PubMed: 19442180]
- Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium. Patterson N, Daly MJ, Price AL, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics*. 2015; 47:291–295. [PubMed: 25642630]
- Carleton RN, Thibodeau MA, Teale MJ, Welch PG, Abrams MP, Robinson T, Asmundson GJ. The Center for Epidemiologic Studies Depression Scale: a review with a theoretical and empirical examination of item content and factor structure. *PLOS ONE*. 2013; 8:e58067. [PubMed: 23469262]
- Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. *American Journal of Psychiatry*. 1976; 133:1181–1186. [PubMed: 788529]
- Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). *American Journal of Cardiology*. 2003; 92:522–528. [PubMed: 12943870]
- CONVERGE Consortium. Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature*. 2015; 523:588–591. [PubMed: 26176920]
- Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. *American Journal of Public Health and the Nation's Health*. 1951; 41:279–281.

- Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS, van Dyck R, de Geus EJ, Hofman A, Uitterlinden AG, Hottenga JJ, Nolen WA, Oostra BA, Sullivan PF, Willemsen G, Zitman FG, Tiemeier H, Janssens AC, Boomsma DI, van Duijn CM, Middeldorp CM. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. *Molecular Psychiatry*. 2011; 16:773–783. [PubMed: 20567237]
- Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. *Preventive Medicine*. 1975; 4:518–525. [PubMed: 1208363]
- Galecka E, Szymraj J, Florkowski A, Galecki P, Bie kiewicz M, Karbownik-Lewi ska M, Lewi ski A. Single nucleotide polymorphisms and mRNA expression for melatonin MT₂ receptor in depression. *Psychiatry Research*. 2011; 189:472–474. [PubMed: 21353709]
- Goldstein JA. Melatonin as depression marker. *Biological Psychiatry*. 1985; 20:585. [PubMed: 3986262]
- Hek K, Demirkan A, Lahti J, Terracciano A, Teumer A, Cornelis MC, Amin N, Bakshis E, Baumert J, Ding J, Liu Y, Marcianti K, Meirelles O, Nalls MA, Sun YV, Vogelzangs N, Yu L, Bandinelli S, Benjamin EJ, Bennett DA, Boomsma D, Cannas A, Coker LH, de Geus E, De Jager PL, Diez-Roux AV, Purcell S, Hu FB, Rimm EB, Hunter DJ, Jensen MK, Curhan G, Rice K, Penman AD, Rotter JJ, Sotoodehnia N, Emeny R, Eriksson JG, Evans DA, Ferrucci L, Fornage M, Gudnason V, Hofman A, Illig T, Kardina S, Kelly-Hayes M, Koenen K, Kraft P, Kuningas M, Massaro JM, Melzer D, Mulas A, Mulder CL, Murray A, Oostra BA, Palotie A, Penninx B, Petersmann A, Pilling LC, Psaty B, Rawal R, Reiman EM, Schulz A, Shulman JM, Singleton AB, Smith AV, Sutin AR, Uitterlinden AG, Volzke H, Widen E, Yaffe K, Zonderman AB, Cucca F, Harris T, Ladwig KH, Llewellyn DJ, Raikkonen K, Tanaka T, van Duijn CM, Grabe HJ, Launer LJ, Lunetta KL, Mosley TH Jr, Newman AB, Tiemeier H, Murabito J. A genome-wide association study of depressive symptoms. *Biological Psychiatry*. 2013; 73:667–678. [PubMed: 23290196]
- Hill SM, Cheng C, Yuan L, Mao L, Jockers R, Dauchy B, Blask DE. Age-related decline in melatonin and its MT₁ receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. *Current Aging Science*. 2013; 6:125–133. [PubMed: 23895529]
- Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, Kuipers EJ, Nijsten TE, Stricker BH, Tiemeier H, Uitterlinden AG, Vernooij MW, Witteman JC. The Rotterdam Study: 2012 objectives and design update. *European Journal of Epidemiology*. 2011; 26:657–686. [PubMed: 21877163]
- Jang KL, Livesley WJ, Taylor S, Stein MB, Moon EC. Heritability of individual depressive symptoms. *Journal of Affective Disorders*. 2004; 80:125–133. [PubMed: 15207925]
- Juster FT, Suzman R. An overview of the Health and Retirement Study. *Journal of Human Resources*. 1995; 30(Suppl):S7–S56.
- Keers R, Uher R. Gene–environment interaction in major depression and antidepressant treatment response. *Current Psychiatry Reports*. 2012; 14:129–137. [PubMed: 22198824]
- Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, Czamara D, Alexander M, Salyakina D, Ripke S, Hoehn D, Specht M, Menke A, Hennings J, Heck A, Wolf C, Ising M, Schreiber S, Czisch M, Muller MB, Uhr M, Bettecken T, Becker A, Schramm J, Rietschel M, Maier W, Bradley B, Ressler KJ, Nothen MM, Cichon S, Craig IW, Breen G, Lewis CM, Hofman A, Tiemeier H, van Duijn CM, Holsboer F, Muller-Myhsok B, Binder EB. The neuronal transporter gene *SLC6A15* confers risk to major depression. *Neuron*. 2011; 70:252–265. [PubMed: 21521612]
- López-León S, Aulchenko YS, Tiemeier H, Oostra BA, van Duijn CM, Janssens AC. Shared genetic factors in the co-occurrence of symptoms of depression and cardiovascular risk factors. *Journal of Affective Disorders*. 2010; 122:247–252. [PubMed: 19674795]
- López-León S, Chi Choy W, Aulchenko YS, Claes SJ, Oostra BA, Mackenbach JP, van Duijn CM, Janssens ACJW. Genetic factors influence the clustering of depression among individuals with lower socioeconomic status. *PLoS ONE*. 2009; 4:e5069. [PubMed: 19333388]
- Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, Byrne EM, Blackwood DH, Boomsma DI, Cichon S, Heath AC, Holsboer F, Lucae S, Madden PA, Martin NG, McGuffin P, Muglia P, Nothen MM, Penninx BP, Pergadia ML, Potash JB, Rietschel M, Lin D, Muller-Myhsok B, Shi J, Steinberg S, Grabe HJ, Lichtenstein P, Magnusson P, Perlis RH, Preisig M, Smoller JW,

Stefansson K, Uher R, Kutalik Z, Tansey KE, Teumer A, Viktorin A, Barnes MR, Bettecken T, Binder EB, Breuer R, Castro VM, Churchill SE, Coryell WH, Craddock N, Craig IW, Czamara D, De Geus EJ, Degenhardt F, Farmer AE, Fava M, Frank J, Gainer VS, Gallagher PJ, Gordon SD, Goryachev S, Gross M, Guipponi M, Henders AK, Herms S, Hickie IB, Hoefels S, Hoogendijk W, Hottenga JJ, Iosifescu DV, Ising M, Jones I, Jones L, Jung-Ying T, Knowles JA, Kohane IS, Kohli MA, Korszun A, Landen M, Lawson WB, Lewis G, Macintyre D, Maier W, Mattheisen M, McGrath PJ, McIntosh A, McLean A, Middeldorp CM, Middleton L, Montgomery GM, Murphy SN, Nauck M, Nolen WA, Nyholt DR, O'Donovan M, Oskarsson H, Pedersen N, Schefters WA, Schulz A, Schulze TG, Shyn SI, Sigurdsson E, Slager SL, Smit JH, Stefansson H, Steffens M, Thorgeirsson T, Tozzi F, Treutlein J, Uhr M, van den Oord EJ, Van Grootheest G, Volzke H, Weiburg JB, Willemsen G, Zitman FG, Neale B, Daly M, Levinson DF, Sullivan PF. A mega-analysis of genome-wide association studies for major depressive disorder. *Molecular Psychiatry*. 2013; 18:497–511. [PubMed: 22472876]

Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, Antoniadis A, Domenici E, Perry J, Rothen S, Vandeleur CL, Mooser V, Waeber G, Vollenweider P, Preisig M, Lucae S, Muller-Myhsok B, Holsboer F, Middleton LT, Roses AD. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. *Molecular Psychiatry*. 2008; 15:589–601. [PubMed: 19107115]

National Institute for Clinical Excellence. NI Draft Guidelines CE Depression: the Management of Depression in Primary and Secondary Care. National Institute for Clinical Excellence; London: 2003.

Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, Cardinali DP. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. *Progress in Neurobiology*. 2008; 85:335–353. [PubMed: 18571301]

Pfaffenrath V, Fendrich K, Vennemann M, Meisinger C, Ladwig KH, Evers S, Straube A, Hoffmann W, Berger K. Regional variations in the prevalence of migraine and tension-type headache applying the new IHS criteria: the German DMKG Headache Study. *Cephalalgia*. 2009; 29:48–57. [PubMed: 18771491]

Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, Lai S, Usala G, Lai M, Loi P, Mameli C, Vacca L, Deiana M, Olla N, Masala M, Cao A, Najjar SS, Terracciano A, Nedorezov T, Sharov A, Zonderman AB, Abecasis GR, Costa P, Lakatta E, Schlessinger D. Heritability of cardiovascular and personality traits in 6148 Sardinians. *PLoS Genetics*. 2006; 2:e132. [PubMed: 16934002]

Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JJ, Uitterlinden AG, Harris TB, Witteman JC, Boerwinkle E, CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circulation: Cardiovascular Genetics*. 2009; 2:73–80. [PubMed: 20031568]

Psychiatric GWAS Case Control Consortium. Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, Kelsoe J, Lehner T, Levinson DF, Moran A, Sklar P, Sullivan PF. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. *American Journal of Psychiatry*. 2009; 166:540–556. [PubMed: 19339359]

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American Journal of Human Genetics*. 2007; 81:559–575. [PubMed: 17701901]

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. *Applied Psychological Measurement*. 1977; 3:385–401.

Rahman I, Bennet AM, Pedersen NL, de Faire U, Svensson P, Magnusson PK. Genetic dominance influences blood biomarker levels in a sample of 12,000 Swedish elderly twins. *Twin Research and Human Genetics*. 2009; 12:286–294. [PubMed: 19456221]

Rietveld CA, Medland SE, Derringer J, Yang J, Esko T, Martin NW, Westra HJ, Shakhbazov K, Abdellaoui A, Agrawal A, Albrecht E, Alizadeh BZ, Amin N, Barnard J, Baumeister SE, Benke KS, Bielak LF, Boatman JA, Boyle PA, Davies G, de Leeuw C, Eklund N, Evans DS, Ferhmann R, Fischer K, Gieger C, Gjessing HK, Hagg S, Harris JR, Hayward C, Holzapfel C, Ibrahim-Verbaas CA, Ingelsson E, Jacobsson B, Joshi PK, Jugessur A, Kaakinen M, Kanoni S, Karjalainen J, Kolcic I, Kristiansson K, Kutalik Z, Lahti J, Lee SH, Lin P, Lind PA, Liu Y, Lohman K, Loitfelder

M, McMahon G, Vidal PM, Meirelles O, Milani L, Myhre R, Nuotio ML, Oldmeadow CJ, Petrovic KE, Peyrot WJ, Polasek O, Quaye L, Reinmaa E, Rice JP, Rizzi TS, Schmidt H, Schmidt R, Smith AV, Smith JA, Tanaka T, Terracciano A, van der Loos MJ, Vitart V, Volzke H, Wellmann J, Yu L, Zhao W, Allik J, Attia JR, Bandinelli S, Bastardot F, Beauchamp J, Bennett DA, Berger K, Bierut LJ, Boomsma DI, Bultmann U, Campbell H, Chabris CF, Cherkas L, Chung MK, Cucca F, de Andrade M, De Jager PL, De Neve JE, Deary IJ, Dedoussis GV, Deloukas P, Dimitriou M, Eiriksdottir G, Elderson MF, Eriksson JG, Evans DM, Faul JD, Ferrucci L, Garcia ME, Gronberg H, Guethnason V, Hall P, Harris JM, Harris TB, Hastie ND, Heath AC, Hernandez DG, Hoffmann W, Hofman A, Holle R, Holliday EG, Hottenga JJ, Iacono WG, Illig T, Jarvelin MR, Kahonen M, Kaprio J, Kirkpatrick RM, Kowgier M, Latvala A, Launer LJ, Lawlor DA, Lehtimaki T, Li J, Lichtenstein P, Lichtner P, Liewald DC, Madden PA, Magnusson PK, Makinen TE, Masala M, McGue M, Metspalu A, Mielck A, Miller MB, Montgomery GW, Mukherjee S, Nyholt DR, Oostra BA, Palmer LJ, Palotie A, Penninx BW, Perola M, Peyser PA, Preisig M, Raikonen K, Raitakari OT, Realo A, Ring SM, Ripatti S, Rivadeneira F, Rudan I, Rustichini A, Salomaa V, Sarin AP, Schlessinger D, Scott RJ, Snieder H, St Pourcain B, Starr JM, Sul JH, Surakka I, Svento R, Teumer A, S. LifeLines Cohort. Tiemeier H, van Rooij FJ, Van Wagoner DR, Vartiainen E, Viikari J, Vollenweider P, Vonk JM, Waeber G, Weir DR, Wichmann HE, Widen E, Willemsen G, Wilson JF, Wright AF, Conley D, Davey-Smith G, Franke L, Groenen PJ, Hofman A, Johannesson M, Kardina SL, Krueger RF, Laibson D, Martin NG, Meyer MN, Posthuma D, Thurik AR, Timpson NJ, Uitterlinden AG, van Duijn CM, Visscher PM, Benjamin DJ, Cesarini D, Koellinger PD. GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. *Science*. 2013; 340:1467–1471. [PubMed: 23722424]

- Simino J, Shi G, Bis JC, Chasman DI, Ehret GB, Gu X, Guo X, Hwang SJ, Sijbrands E, Smith AV, Verwoert GC, Bragg-Gresham JL, Cadby G, Chen P, Cheng CY, Corre T, de Boer RA, Goel A, Johnson T, Khor CC, S. LifeLines Cohort. Lluís-Ganella C, Luan J, Lyytikäinen LP, Nolte IM, Sim X, Sober S, van der Most PJ, Verweij N, Zhao JH, Amin N, Boerwinkle E, Bouchard C, Dehghan A, Eiriksdottir G, Elosua R, Franco OH, Gieger C, Harris TB, Hercberg S, Hofman A, James AL, Johnson AD, Kahonen M, Khaw KT, Kutalik Z, Larson MG, Launer LJ, Li G, Liu J, Liu K, Morrison AC, Navis G, Ong RT, Papanicolaou GJ, Penninx BW, Psaty BM, Raffel LJ, Raitakari OT, Rice K, Rivadeneira F, Rose LM, Sanna S, Scott RA, Siscovick DS, Stolk RP, Uitterlinden AG, Vaidya D, van der Klauw MM, Vasana RS, Vithana EN, Volker U, Volzke H, Watkins H, Young TL, Aung T, Bochud M, Farrall M, Hartman CA, Laan M, Lakatta EG, Lehtimaki T, Loos RJ, Lucas G, Meneton P, Palmer LJ, Rettig R, Snieder H, Tai ES, Teo YY, van der Harst P, Wareham NJ, Wijmenga C, Wong TY, Fornage M, Gudnason V, Levy D, Palmas W, Ridker PM, Rotter JI, van Duijn CM, Witteman JC, Chakravarti A, Rao DC. Gene–age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. *American Journal of Human Genetics*. 2014; 95:24–38. [PubMed: 24954895]
- Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D’Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O’Donnell CJ, Vasana RS, Wolf PA, Levy D. The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. *American Journal of Epidemiology*. 2007; 165:1328–1335. [PubMed: 17372189]
- Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, Arolt V, Baune BT, Blackwood D, Cichon S, Coventry WL, Domschke K, Farmer A, Fava M, Gordon SD, He Q, Heath AC, Heutink P, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hu Y, Kohli M, Lin D, Lucae S, Macintyre DJ, Maier W, McGhee KA, McGuffin P, Montgomery GW, Muir WJ, Nolen WA, Nothen MM, Perlis RH, Pirlo K, Posthuma D, Rietschel M, Rizzu P, Schosser A, Smit AB, Smoller JW, Tzeng JY, van Dyck R, Verhage M, Zitman FG, Martin NG, Wray NR, Boomsma DI, Penninx BW. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. *Molecular Psychiatry*. 2009; 14:359–375. [PubMed: 19065144]
- Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *American Journal of Psychiatry*. 2000; 157:1552–1562. [PubMed: 11007705]
- Sutin AR, Zonderman AB. Depressive symptoms are associated with weight gain among women. *Psychological Medicine*. 2012; 42:2351–2360. [PubMed: 22475128]
- Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M,

Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Tzee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruukonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllenstein U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altschuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA Jr, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010; 466:707–713. [PubMed: 20686565]

van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV. Power in GWAS: lifting the curse of the clinical cut-off. *Molecular Psychiatry*. 2013; 18:2–3. [PubMed: 22614290]

Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. *International Journal of Epidemiology*. 2010; 39:504–518. [PubMed: 19959603]

Vennemann MM, Hummel T, Berger K. The association between smoking and smell and taste impairment in the general population. *Journal of Neurology*. 2008; 255:1121–1126. [PubMed: 18677645]

Weir, D. *Biosocial Surveys*. National Academies Press; Washington, DC: 2008. Committee on Advances in Collecting and Utilizing Biological Indicators and Genetic Information in Social Science Surveys(chapter editor)

Wetterberg L, Beck-Friis J, Kjellman BF, Ljunggren JG. Circadian rhythms in melatonin and cortisol secretion in depression. *Advances in Biochemical Psychopharmacology*. 1984; 39:197–205. [PubMed: 6464829]

Willer C, Li Y, Abecasis G. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010; 26:2190–2191. [PubMed: 20616382]

Table 1

Study sample characteristics of discovery and replication cohorts

	Somatic items	Negative items	Positive items	Interpersonal items	Age, years	n	Women, %
Discovery sample							
BLSA ^a	2.92 (2.81)	1.42 (2.41)	10.31 (2.45)	0.22 (0.65)	71.6 (13.8)	827	45.1
DHS ^a	2.92 (3.18)	1.54 (2.91)	7.03 (3.25)	0.22 (0.72)	52.4 (13.7)	991	52.6
ERF ^a	3.78 (3.76)	2.07 (3.36)	8.43 (3.40)	0.40 (0.89)	55.0 (10.1)	1107	55.2
FHS ^a	1.05 (0.751)	0.61 (0.75)	0.596 (0.739)	0.15 (0.35)	56.1 (10.5)	6636	51.8
HBCS ^a	3.79 (3.31)	2.00 (3.05)	9.22 (2.40)	0.37 (0.79)	63.4 (2.9)	1360	59.4
HEALTH ABC-Eur ^a	1.68 (2.13)	0.93 (1.85)	10.74 (1.82)	0.13 (0.49)	73.8 (2.8)	1520	46.4
RS I ^a	1.52 (2.61)	1.24 (2.65)	10.36 (2.59)	0.09 (0.42)	72.7 (7.2)	3709	58.1
RS II ^a	1.98 (2.78)	1.34 (2.66)	10.19 (2.60)	0.15 (0.53)	64.8 (8.0)	1995	53.3
RS III ^a	2.66 (3.32)	1.17 (2.58)	10.37 (2.41)	0.18 (0.58)	56.0 (5.7)	1917	55.1
SardinIA ^a	3.27 (2.91)	2.51 (3.08)	4.81 (2.53)	0.48 (0.85)	58.0 (11.4)	2608	58.1
ARIC ^b	2.31 (2.15)	1.19 (1.72)	5.62 (0.95)	0.21 (0.65)	72.7 (5.5)	384	42.1
STR ^b	1.10 (1.60)	0.79 (1.43)	1.22 (1.27)	0.21 (0.58)	57.7 (8.9)	9474	52.7
Replication sample							
FINRISK ^b	1.74 (1.63)	-	-	-	53.1 (13.4)	605	49.7
HRS ^b	1.38 (1.50)	-	-	-	69.3 (5.5)	3753	58.1
InCHIANTI ^a	3.23 (3.18)	-	-	-	66.0 (15.0)	1019	47.0
RUSH-MAP ^b	0.50 (0.80)	-	-	-	80.8 (6.5)	721	71.7
RUSH-ROS ^b	0.57 (0.82)	-	-	-	75.5 (7.2)	715	65.9

Data are given as mean (standard deviation).

n, Number of subjects included; BLSA, Baltimore Longitudinal Study of Aging; DHS, Dortmund Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; HBCS, Helsinki Birth Cohort Study; HEALTH ABC-Eur, Health, Aging and Body Composition study (of European ancestors); RS I-II-III, Rotterdam Study first, second and third waves; SardinIA, study; ARIC, Atherosclerosis Risk in Communities study; STR, Swedish Twin Registry; FINRISK, National FINRISK Study of Finland; HRS, Health and Retirement Study; InCHIANTI, Invechiare in Chianti; RUSH-MAP, Rush Memory and Aging Project; RUSH-ROS, Rush Religious Orders Study; CES-D, Center for Epidemiological Studies Depression.

^a20-item CES-D scale.

10-item CES-D scale.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript